Compounds > pentazirinocyclodiphosphathiazene
Page last updated: 2024-08-25

pentazirinocyclodiphosphathiazene and Benign Neoplasms

pentazirinocyclodiphosphathiazene has been researched along with Benign Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Annyas, AA; Koops, HS; Mulder, NH; Rodenhuis, S; Sleijfer, DT; van den Heuvel, WJ1
Mulder, NH; Rodenhuis, S; Schraffordt Koops, H; Sleijfer, DT; Van de Grampel, JC1
Beneken genaamd Kolmer, MH; Rodenhuis, S; Uges, DR; van de Grampel, JC1
Beneken genaamd Kolmer, MH; Mulder, NH; Rodenhuis, S; Scaf, AH; Sleijfer, DT; Uges, DR; van de Grampel, JC1
Koops, HS; Mulder, NH; Rodenhuis, S; Sleijfer, DT; van de Grampel, JC1
Carpentier, Y; Cattan, A; Coninx, P; Garbe, E; Jezekova, D; Nasca, S1

Other Studies

6 other study(ies) available for pentazirinocyclodiphosphathiazene and Benign Neoplasms

ArticleYear
Patient motivation and informed consent in a phase I study of an anticancer agent.
    European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Azirines; Comprehension; Disclosure; Drug Evaluation; Family; Female; Humans; Informed Consent; Male; Middle Aged; Motivation; Neoplasms; Physician-Patient Relations; Research Subjects; Risk Assessment; Therapeutic Human Experimentation

1984
Phase I evaluation of SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6, 2,4,6,3 lambda 5, 5 lambda 5 thiatriaza-diphosphorine-1-oxide) in a weekly schedule.
    European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Azirines; Bone Marrow Diseases; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia

1984
Determination of the antitumor agent SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6,2,4,6,3 lambda 5, 5 lambda 5 thia-triazadiphosphorine-1-oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man.
    Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:3

    Topics: Aged; Antineoplastic Agents; Azirines; Chromatography, Gas; Drug Evaluation; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms

1983
Clinical pharmacokinetics of (NPAz2)2NSOAz: 'SOAz'.
    Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Azirines; Dose-Response Relationship, Drug; Drug Evaluation; Half-Life; Humans; Kinetics; Male; Middle Aged; Neoplasms

1983
Phase I clinical trial of (NPAz2)2NSOAz: 'SOAz'.
    Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Azirines; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Leukocyte Count; Leukopenia; Male; Middle Aged; Neoplasms; Platelet Count; Thrombocytopenia

1983
Phase I study of SOAz.
    Cancer treatment reports, 1982, Volume: 66, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Azirines; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia

1982